PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
- Details
- Category: AstraZeneca

Bayer aspires to significantly expand Life Science businesses
- Details
- Category: Bayer

GSK announces major new commitment to Asia
- Details
- Category: GlaxoSmithKline

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
- Details
- Category: Novartis

FDA approves Opdivo (nivolumab) for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer
- Details
- Category: Bristol-Myers Squibb

AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
- Details
- Category: AstraZeneca

Novartis announces completion of transactions with GSK
- Details
- Category: Novartis

More Pharma News ...
- Shire acquires Meritage Pharma
- Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
- Sanofi and Lead Pharma to develop treatments for autoimmune diseases
- GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
- Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics
- Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study
- Pfizer to Acquire Hospira